Laverock Therapeutics pushes into in vivo CAR-T and genetic medicine
Laverock Therapeutics is shifting from ex vivo cell therapies to launch in vivo CAR-T and genetic medicine programs. The company aims to tackle solid tumors and tough genetic disorders using programmable gene control.